New Bioporto president embroiled in investigation of violation of US federal law
New president of Danish Bioporto's US subsidiary, Amy Winslow, joins Bioporto from a US firm charged with FDA investigations and investor lawsuits because of a defective product. According to Bioporto's CEO, Winslow did not create the problems but worked to solve them.
Amy Winslow, the new president of Danish Bioporto's US subsidiary, is involved in an inconvenient case of violation of US federal law.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
